54 마리의 외이염에 이환된 개에서 하이드로코티손 아세포네이트-겐타마이신-미코나졸 국소 혼합제제인 이소틱($Easotic^{(R)}$, Virbac, Carros, France)의 효과를 평가하였다. 외이염 환자들은 이소틱을 하루 1번 적용하여 5일 동안 치료 받았고 2일 동안 휴약 하였으며 처음 적용일로부터 7일 후 평가되었다. 적용 후에 외이염이 지속되는 경우 추가적으로 이소틱을 하루 1번 5일 동안 사용하고 2일 휴약 후에 처음 적용일로부터 14일 후 평가되었다. 이소틱의 효과를 평가하기 위해 8항목의 임상증상을 증상의 심한 정도로 등급을 매겨 점수화하였고 귀의 도말 표본에서 감염인자들을 준정량적으로 등급을 매겨 점수화하였다. 임상증상점수와 감염인자점수의 합을 전체임상점수로 정의하였다. 이소틱을 5일 동안 적용하였을 때 전체임상점수는 76% 감소하였다. 이소틱을 10일 동안 적용하였을 때 처음 5일 동안 전체임상점수는 46.6% 감소하였다. 추가적인 5일간 적용 후 처음 적용할 때와 비교하여 전체임상점수는 82.2% 감소하였다. 모든 케이스에서 실험 기간 동안 치료제와 관련된 부작용은 나타나지 않았다. 따라서 5일 간 이소틱 치료 및 10일 간 이소틱 치료는 개의 외이염을 치료하는데 있어서 효과적이고 안전한 방법으로 생각된다.
54 마리의 외이염에 이환된 개에서 하이드로코티손 아세포네이트-겐타마이신-미코나졸 국소 혼합제제인 이소틱($Easotic^{(R)}$, Virbac, Carros, France)의 효과를 평가하였다. 외이염 환자들은 이소틱을 하루 1번 적용하여 5일 동안 치료 받았고 2일 동안 휴약 하였으며 처음 적용일로부터 7일 후 평가되었다. 적용 후에 외이염이 지속되는 경우 추가적으로 이소틱을 하루 1번 5일 동안 사용하고 2일 휴약 후에 처음 적용일로부터 14일 후 평가되었다. 이소틱의 효과를 평가하기 위해 8항목의 임상증상을 증상의 심한 정도로 등급을 매겨 점수화하였고 귀의 도말 표본에서 감염인자들을 준정량적으로 등급을 매겨 점수화하였다. 임상증상점수와 감염인자점수의 합을 전체임상점수로 정의하였다. 이소틱을 5일 동안 적용하였을 때 전체임상점수는 76% 감소하였다. 이소틱을 10일 동안 적용하였을 때 처음 5일 동안 전체임상점수는 46.6% 감소하였다. 추가적인 5일간 적용 후 처음 적용할 때와 비교하여 전체임상점수는 82.2% 감소하였다. 모든 케이스에서 실험 기간 동안 치료제와 관련된 부작용은 나타나지 않았다. 따라서 5일 간 이소틱 치료 및 10일 간 이소틱 치료는 개의 외이염을 치료하는데 있어서 효과적이고 안전한 방법으로 생각된다.
Fifty-four dogs with otitis externa were enrolled in the study for the Evaluation of efficacy of a Hydrocortisone aceponate - Gentamicin - Miconazole otic combination ($Easotic^{(R)}$, Virbac, Carros, France). Otitis externa patients were treated by $Easotic^{(R)}$ once daily f...
Fifty-four dogs with otitis externa were enrolled in the study for the Evaluation of efficacy of a Hydrocortisone aceponate - Gentamicin - Miconazole otic combination ($Easotic^{(R)}$, Virbac, Carros, France). Otitis externa patients were treated by $Easotic^{(R)}$ once daily for 5 days and 2 days off treatment and evaluated on $7^{th}$ day. If otitis externa persisted, additional $Easotic^{(R)}$ treatment was administered once daily for 5 days and rested 2 days and reevaluated on $14^{th}$ day. For the evaluation of efficacy of $Easotic^{(R)}$, eight clinical signs were scored on a severity scale and infectious agents from ear sample were also graded using semi-quantitative scale at each visit. Sum of clinical scores and cytological scores was defined as Global Clinical Score. When $Easotic^{(R)}$ was applied once daily for 5 days, global clinical score was reduced 76.0%. When $Easotic^{(R)}$ was administered for 10 days, during first 5 days administration, 46.6% reduction of global clinical score was detected. During additional 5 days administration, 82.2% reduction of global clinical score was observed compared with Day 0. Any relevant adverse effect was not reported during the study in all cases. Thus, $Easotic^{(R)}$ treatment once daily for 5 days and 10 days appears to be effective and safe treatment for canine otitis externa.
Fifty-four dogs with otitis externa were enrolled in the study for the Evaluation of efficacy of a Hydrocortisone aceponate - Gentamicin - Miconazole otic combination ($Easotic^{(R)}$, Virbac, Carros, France). Otitis externa patients were treated by $Easotic^{(R)}$ once daily for 5 days and 2 days off treatment and evaluated on $7^{th}$ day. If otitis externa persisted, additional $Easotic^{(R)}$ treatment was administered once daily for 5 days and rested 2 days and reevaluated on $14^{th}$ day. For the evaluation of efficacy of $Easotic^{(R)}$, eight clinical signs were scored on a severity scale and infectious agents from ear sample were also graded using semi-quantitative scale at each visit. Sum of clinical scores and cytological scores was defined as Global Clinical Score. When $Easotic^{(R)}$ was applied once daily for 5 days, global clinical score was reduced 76.0%. When $Easotic^{(R)}$ was administered for 10 days, during first 5 days administration, 46.6% reduction of global clinical score was detected. During additional 5 days administration, 82.2% reduction of global clinical score was observed compared with Day 0. Any relevant adverse effect was not reported during the study in all cases. Thus, $Easotic^{(R)}$ treatment once daily for 5 days and 10 days appears to be effective and safe treatment for canine otitis externa.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
For objectivity and accuracy of clinical sign scores, this study was conducted by veterinary dermatologist. Within the clinical signs, erythema, pruritus and exudates were common signs of otitis externa, frequently reported on the other studies of otitis externa (20,24,25).
The objective of this study is to evaluate the in vivo efficacy of a topical ear suspension (Easotic®, Virbac) containing hydrocortisone aceponate - gentamicin - miconazole for the treatment of otitis externa in dogs by using clinical and cytological score.
제안 방법
If the clinical signs of otitis externa persisted on second visit (Day 7), additional treatment with 5 days administration and 2 days off was performed and re-evaluated every 7th day (Day 14, Day 21) until the improvement of clinical sign was enough to stop the treatment.
대상 데이터
Forty nine dogs (54 cases) were recruited for the study from April 2010 to August 2011. Breeds represented in the study included Cocker spaniel (15 cases, 27.
이론/모형
Organisms were estimated from 10 consecutive microscope fields at higher magnification field (1000×) by same veterinarian to reduce the individual differences. Cytological score was calculated by using a semi-quantitative scale for bacterial and fungal count (Table 1). Sum of the clinical and cytological score gives global clinical score from 0 to 31.
성능/효과
was evaluated at Day 0, Day 7 and Day 14. All scores significantly decreased, especially excoriation-crust, pain and rod score diminished 100% at the end of the study. Compared with Standard Treatment Group, Suppuration and Rod scored significantly higher than other scores.
All scores were significantly reduced except stenosis, including excoriation-crust (91.4%), suppuration (90.9%), pain (88.4%), pruritus (72.9%), exudates (74.1%) (*P < 0.05).
7% between first visit (Day 0) and second visit (Day 7) (Fig 1). As a each score reduction between Day 0 and Day 7, over the 80% reduction was considered excoriation-crust (91.4%), suppuration (90.9%), pain (88.4%) and rod (84.6%) were included. 70~80% reduction included scores of pruritus (72.
In this study, Easotic® administration to the otitis externa patients showed great improvement of clinical sign and the number of infectious agents were reduced significantly with one or more treatments.
Malassezia also increases moisture and surface lipids, so it causes erythematous-ceruminus otitis externa (5,16). In this study, rapid decrease of malassezia score was observed, 77% reduction on Day 7 in Standard Treatment Group and, 86.9% reduction on Day 14 in Additional Treatment Group.
참고문헌 (28)
Bensignor E, Grandemange E. Comparison of an antifungal agent with a mixture of antifungal, antibiotic and corticosteroid agents for the treatment of Malassezia species otitis in dogs. Vet Rec 2006; 158: 193-195.
Bonneau S, Skowronski V, Sanquer A, Maynard L, Eun HM. Therapeuic efficacy of topical hydrocortisone aceponate in experimental flea-allegy dermatitis in dogs. Aust Vet J 2009; 87: 287-291.
Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58.
Cafarchia C, Gallo S, Capelli G, Otranto D. Occurrence and population size of Malassezia spp in the external ear canal of dogs and cats both healthy and with otitis. Mycopathologia 2005; 160: 143-149.
Coutinho SD, Paula CR. Proteinase, phospholipase, hyaluronidase and chondroitin-sulphatase production by Malassezia pachydermatis. Medical Mycol 2000; 38: 73.
Foster AP, DeBoer DJ. The role of Pseudomonas in canine ear disease. Comp Cont Ed Pract Vet 1998; 20: 909-919
Guedeja-Marron J, Blanco JL, Ruperez C, Garcia ME. Susceptibility of Bacterial Isolates from Chronic Canine Otitis Externa to Twenty Antibiotics. J Vet Med 1998; 45: 507-512.
Hariharan H, McPhee L, Heaney S, Bryenton J. Antimicrobial drug susceptibility of clinical isolates of Pseudomonas aeruginosa. Can Vet J 1995; 36: 166-168.
Hill PB, Lo A, Aden CA, Huntley S, Morey V, Ramsey S, Richardson C, Smith DJ, Sutton C, Tayler MD, Thrope E, Tidmarsh R, Williams V. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animal practice. Vet Rec 2006; 158: 533-539.
Junco MTT, martin Barrasa JL. Identification and antimicrobial susceptibility of coagulase positive staphylococci isolated from healthy dogs and dogs suffering otitis externa. J Vet Med 2002; 49: 419-423.
Kowalski JJ. The microbial environment of the ear canal in health and disease. Vet Clin North Am Small Anim Pract 1988; 18: 743-754.
Lilenbaum W, Veras M, Blum E, Souza GN, Antimicrobial susceptibility of staphylococci isolated from otitis externa in dogs. Lett Appl Microbiol 2000; 31: 42-45.
Lyskova P, Vydrzalova M, Mazurova J. Identification and Antimicrobial susceptibility of bacteria and yeasts isolated from healthy dogs and dogs with otitis externa. J Vet Med 2007; 54: 559-563.
Nardoni S, Mancianti F, Coraza M, Rum A. Occurrence of Malassezia species in healthy and dermatologically diseases dogs. Mycophthologia 2004; 157: 383-388.
Nuttall T, Mueller R, Bensignor E, Verde M, Noli C, Schmidt V, Reme CA. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomized, double blind, placebo controlled trial. Vet dermatol 2009; 20: 191-198.
Prado MR, Brilhante RS, Cordeiro RA, Monteiro AJ, Sidrim JJ, Rocha MF, Frequency of yeasts and dermatophytes from healthy and diseased dogs. J Vet Diagn Invest 2008; 20: 197- 202.
Radinsky MA, Mason D. Diseases of the ear. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary Internal medicine, 7th ed, Elsevier, Saintlouis, 2010: 1015-1020.
Rigaut D, Sanquer A, Maynard L, Reme CA, Efficacy of a topical ear formulation with a pump delivery system for the treatment of infectious otitis externa in dogs: a randomized controlled trial. Intern J Appl Res Vet Med 2011; 9: 15-28.
Rougier S, Borell D, Pheulpin S, Woehrle F, Boisrame B. A comparative study of two antimicrobial anti-inflammatory formulations in the treatment of canine otitis externa. Vet Dermatol 2005; 16: 299-307.
Reme CA, Dufour P. Effects of repeated topical application of a 0.0584% hydrocortisone aceponate spray on skin thickness in beagle dogs. Intern J Appl Res Vet Med 2010; 8: 1-6.
Saridomichelakis MN, Farmaki R, Leontides LS, Koutinas AF. Aetiology of canine otitis externa a retrospectivestudy of 100 cases. Vet Dermatol 2007; 18: 341-347.
Scott DW, Miller WH, Griffin CE. External ear disease. In: Small Animal Dermatology, 6th ed. Philadelphia, PA: W.B. Saunders, 2001: 1203-1235.
Seol B, Naglic T, Madic J, Bedekovic M. In vitro antimicrobial susceptibility of 183 Pseudomonas aeruginosa strains isolated from dogs to selected antipseudomonal agents. J Vet med 2002; 49: 188-192.
Van Gerven F, Odds FC. The anti-malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrumazole, miconazole and sertaconazole. Mycoses 1995; 38: 389-393.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.